

# Antibiotic Susceptibility of *Pseudomonas aeruginosa* ATCC® BAA-3306™

| Antimicrobial              | MIC <sup>a</sup> | Interpretation <sup>b</sup> | Antimicrobial                | MIC <sup>a</sup> | Interpretation <sup>b</sup> |
|----------------------------|------------------|-----------------------------|------------------------------|------------------|-----------------------------|
| Amikacin                   | ≥64              | R                           | Gentamicin                   | ≥16              | R                           |
| Cefazolin                  | ≥64              | R                           | Imipenem                     | ≥16              | R                           |
| Cefepime                   | 16               | I                           | Levofloxacin                 | 0.25             | S                           |
| Ceftazidime                | 32               | R                           | Meropenem                    | 8                | I                           |
| Ceftazidime/Avibactam      | ≥R               | R                           | Piperacillin /<br>Tazobactam | ≥128             | R                           |
| Ceftolozane/<br>Tazobactam | ≥32              | R                           | Ticarcillin/<br>Avibactam    | ≥128             | R                           |
| Ciprofloxacin              | ≤0.25            | S                           | Tobramycin                   | ≥16              | R                           |

<sup>a</sup> Antibiotic susceptibility was obtained using a Vitek2 AST-GN69 and AST-XN09 cards.

<sup>b</sup> Parameter set: MIC Interpretation Guideline: CLSI M100-S27 (2017)  
Therapeutic Interpretation Guideline: Natural Resistance